Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C
Authors:
- 21 June 2021
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 41 (11) , 2601-2610
Abstract
Background & Aims: Shortening the treatment duration for chronic hepatitis C may increase feasibility and reduce the cost of cure. The aims of this study were to compare 4 weeks of glecaprevir/pibrentasvir (GLE/PIB) treatment with and without ribavirin for patients with chronic hepatitis C and favourable baseline characteristics and to monitor the development of resistance‐associated substitutions (RAS) and re‐treatment outcomes if treatment failed.Methods: We performed an open‐label single‐centre randomized controlled trial, in which patients with chronic hepatitis C were randomized 1:1 to GLE/PIB ± ribavirin, stratified by genotype 3. The main inclusion criteria were treatment‐naive patients, aged 18‐49 with all genotypes accepted, and absence of liver fibrosis, determined by liver stiffness measurement less than 8 kPa. Viral genome sequences were determined by deep sequencing at baseline and at the time of relapse.Results: A total of 32 patients started treatment. Sustained virological response at week 12 (SVR12) was 59% (10/17) for GLE/PIB without ribavirin and 73% (11/15) for GLE/PIB with ribavirin. Drug target‐specific NS5A RAS were detected at baseline for 45% (5/11) of patients with treatment failure and for 14% (3/21) of patients who achieved SVR12. Ten failure patients were retreated 12 weeks with sofosbuvir‐based regimens; all have been cured.Conclusions: In this pilot study of 4‐week treatment with GLE/PIB with and without ribavirin, we found that baseline RAS were more frequent in patients with virological failure. Development of RAS did occur after short treatment but did not result in retreatment failure with a different regimen.EudraCT no: 2017‐005179‐21.Keywords
Funding Information
- Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat
- Kræftens Bekæmpelse
- Novo Nordisk Fonden
This publication has 41 references indexed in Scilit:
- Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free RegimensGastroenterology, 2016
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practiceJournal of Hepatology, 2016
- Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvirAIDS, 2016
- Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 InfectionAnnals of Internal Medicine, 2015
- Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceAntimicrobial Agents and Chemotherapy, 2015
- Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus InfectionAnnals of Internal Medicine, 2015
- Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensClinical Infectious Diseases, 2015
- From non-A, non-B hepatitis to hepatitis C virus cureJournal of Hepatology, 2015
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)The Lancet Infectious Diseases, 2015
- Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 InfectionGastroenterology, 2014